Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of new scientific data and events taking place during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C., April 10-13, 2026.

Forty-five presentations and posters will highlight the results of studies evaluating the company's broad portfolio of products, including the ELIOS™ minimally-invasive glaucoma surgery (MIGS) system*, enVista Envy™ Full Visual Range and enVista Aspire™ intraocular lenses (IOLs), MIEBO® (perfluorohexyloctane ophthalmic solution), ScoutPro® point-of-care osmolarity testing device, Stellaris Elite® Vision Enhancement System, TENEO™ Excimer Laser Platform and XIIDRA® (lifitegrast ophthalmic solution) 5%.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.